475-11-6

Basic information

• Product Name: N-METHYL-L-PROLINE MONOHYDRATE
• Synonyms: N-ME-L-PROLINE HYDROCHLORIDE;N-ME-PROLINE;N-ME-PRO-OH;N-ME-PRO-OH HCL;N-METHYL-L-PROLINE;N-METHYL-L-PROLINE MONOHYDRATE;PYRD(2)-OH H2O;N-ALPHA-METHYL-L-PROLINE
• CAS NO: 475-11-6
• Molecular Formula: C₆H₁₁NO₂
• Molecular Weight: 129.16
• Product Categories: Amino Acids;I - Z;Modified Amino Acids;amino acids
• Mol File: 475-11-6.mol
• Article Data: 47

Chemical Properties

• Melting Point: 114-116 °C(lit.)
• Boiling Point: 227℃
• Flash Point: 91.1℃
• Appearance: White to off-white/Powder
• Density: 1.153
• Vapor Pressure: 0.0286mmHg at 25°C
• Refractive Index: 1.5000
• Storage Temp.: −20°C
• PKA: 2.37±0.20(Predicted)
• Water Solubility: Soluble in water and methanol(both 50 mg/ml-clear-colorless solution)
• CAS DataBase Reference: N-METHYL-L-PROLINE MONOHYDRATE(CAS DataBase Reference)
• NIST Chemistry Reference: N-METHYL-L-PROLINE MONOHYDRATE(475-11-6)
• EPA Substance Registry System: N-METHYL-L-PROLINE MONOHYDRATE(475-11-6)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 475-11-6(Hazardous Substances Data)

Usage

Uses

N-Methyl-L-proline, is an aminoacid which is widely used in pharmaceuticals and food industry.

Definition

ChEBI: An L-proline derivative obtained by replacement of the amino hydrogen by a methyl group.

InChI:InChI=1/C6H11NO2/c1-7-4-2-3-5(7)6(8)9/h5H,2-4H2,1H3,(H,8,9)/t5-/m0/s1

Upstream product

• 50-00-0 formaldehyd 
• 7776-34-3 L-proline hydrochloride 
• 147-85-3 L-proline 
• 124-38-9 carbon dioxide 
• 265660-44-4 (2S)-(+)-N-methyl-2-tributylstannylpyrrolidine 
• 344-25-2 D-Prolin 
• 67-56-1 methanol 
• 471-87-4 L-proline betaine 
• 104097-12-3 1-methyl-3-(1-methyl-pyrrolidin-2-yl)-1H-pyridin-2-one 
• 7664-93-9 sulfuric acid 

Downstream Products

• 471-87-4 L-proline betaine 
• 34381-71-0 (S)-2-hydroxymethyl-1-methylpyrrolidine 
• 1082985-08-7 C₁₂H₁₀F₅NO₂ 
• 1105044-40-3 (2S,2'S)-[(1S,2S)-1,2-bis(4-tert-butylphenyl)ethane-1,2-diyl] bis[1-methylpyrrolidine-2-carboxylate] 
• 1105044-36-7 (2S,2'S)-[(1S,2S)-1,2-diphenylethane-1,2-diyl] bis[1-methylpyrrolidine-2-carboxylate] 
• 1022161-75-6 (2S,2'S)-N,N'-[(1S,2S)-1,2-diphenylethane-1,2-diyl] bis(1-methylpyrrolidine-2-carboxamide) 
• 1105044-54-9 (2R,2'R)-N,N'-[(1R,2R)-1,2-diphenylethane-1,2-diyl] bis(1-methylpyrrolidine-2-carboxamide) 
• 1105044-55-0 (2S,2'S)-N,N'-[(1R,2R)-1,2-diphenylethane-1,2-diyl] bis(1-methylpyrrolidine-2-carboxamide) 
• 1105044-39-0 (2S,2'S)-[(1S,2S)-1,2-bis(4-methoxyphenyl)ethane-1,2-diyl] bis[1-methylpyrrolidine-2-carboxylate] 
• 1105044-38-9 (2S,2'S)-[(1S,2S)-1,2-bis(4-fluorophenyl)ethane-1,2-diyl] bis[1-methylpyrrolidine-2-carboxylate] 
• 1005784-67-7 N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1-methyl-L-prolinamide 
• 207918-15-8 (2S,3R)-cis-3-hydroxy-N-methyl-L-proline 

Relevant articles and documents

Leonurine derivative and application thereof in preparing medicine for preventing or treating ischemic cerebrovascular diseases

The invention provides a leonurine derivative and application of the leonurine derivative in preparation of a medicine for preventing or treating ischemic cerebrovascular diseases. The leonurine derivative has a structure as shown in a general formula (I), wherein X is selected from O or NH; Y is selected from any one of natural amino acid, substituted amino acid or amino alcohol; Z is selected from H, proline and any substituted proline. Pharmacological experiments prove that the leonurine derivative provided by the invention has the effects of neuroprotection, cerebral infarction area reduction and animal neurobehavioral scoring, and is good in safety, so that the leonurine derivative has important significance for developing novel medicines for preventing or treating ischemic cerebrovascular diseases.

A Copper-Catalyzed Sonogashira Coupling Reaction of Diverse Activated Alkyl Halides with Terminal Alkynes Under Ambient Conditions

We describe a copper-catalyzed Sonogashira coupling reaction of alkyl halides with terminal alkynes under ambient conditions, efficiently providing a versatile tool for the construction of substituted alkynes. A new proline-based N,N,P-ligand is utilized to promote the transformation under a mild reaction condition. Diverse alkyl halides, such as primary and secondary (hetero)benzyl chlorides and bromides, secondary and tertiary α-bromo amides and propargylic bromide, are applicable to provide a wide array of alkynes. (Figure presented.).

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.